CL2009001214A1 - Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos - Google Patents
Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicosInfo
- Publication number
- CL2009001214A1 CL2009001214A1 CL2009001214A CL2009001214A CL2009001214A1 CL 2009001214 A1 CL2009001214 A1 CL 2009001214A1 CL 2009001214 A CL2009001214 A CL 2009001214A CL 2009001214 A CL2009001214 A CL 2009001214A CL 2009001214 A1 CL2009001214 A1 CL 2009001214A1
- Authority
- CL
- Chile
- Prior art keywords
- treatment
- pharmaceutical composition
- modulators
- serine proteases
- thromboembolic disorders
- Prior art date
Links
- 102000012479 Serine Proteases Human genes 0.000 title abstract 2
- 108010022999 Serine Proteases Proteins 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009424 thromboembolic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 title 1
- 150000002391 heterocyclic compounds Chemical class 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5431008P | 2008-05-19 | 2008-05-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2009001214A1 true CL2009001214A1 (es) | 2010-12-31 |
Family
ID=41066042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2009001214A CL2009001214A1 (es) | 2008-05-19 | 2009-05-18 | Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8148363B2 (enExample) |
| EP (2) | EP2300435A2 (enExample) |
| JP (1) | JP5504259B2 (enExample) |
| CN (1) | CN102099340A (enExample) |
| AR (1) | AR071823A1 (enExample) |
| CA (1) | CA2724430A1 (enExample) |
| CL (1) | CL2009001214A1 (enExample) |
| MX (1) | MX2010012635A (enExample) |
| PE (1) | PE20091972A1 (enExample) |
| TW (1) | TW201008930A (enExample) |
| WO (1) | WO2009143039A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010149755A1 (en) * | 2009-06-26 | 2010-12-29 | Novartis Ag | 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17 |
| US8242284B1 (en) * | 2009-09-21 | 2012-08-14 | The United States Of America As Represented By The United States Department Of Energy | Anti-cancer agents based on 6-trifluoromethoxybenzimidazole derivatives and method of making |
| RU2017144535A (ru) | 2010-03-30 | 2019-02-18 | Версеон Корпорейшн | Мультизамещенные ароматические соединения в качестве ингибиторов тромбина |
| KR20130088138A (ko) * | 2010-06-28 | 2013-08-07 | 바이엘 인텔렉쳐 프로퍼티 게엠베하 | 농약으로서 사용하기 위한 헤테로아릴-치환된 피리딘 화합물 |
| US8748442B2 (en) | 2010-06-30 | 2014-06-10 | Ironwood Pharmaceuticals, Inc. | sGC stimulators |
| RU2582679C2 (ru) | 2010-11-09 | 2016-04-27 | Айронвуд Фармасьютикалз, Инк. | СТИМУЛЯТОРЫ sGC |
| EA023064B1 (ru) | 2011-04-28 | 2016-04-29 | Новартис Аг | ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ |
| US9161924B2 (en) | 2011-07-08 | 2015-10-20 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| EP2755652B1 (en) | 2011-09-16 | 2021-06-02 | Novartis AG | N-substituted heterocyclyl carboxamides |
| US9139564B2 (en) | 2011-12-27 | 2015-09-22 | Ironwood Pharmaceuticals, Inc. | 2-benzyl, 3-(pyrimidin-2-yl) substituted pyrazoles useful as sGC stimulators |
| CN102660253B (zh) * | 2012-03-07 | 2014-05-21 | 泰山医学院 | 一种吡唑啉衍生物类Ni2+荧光探针及其应用 |
| WO2014099694A1 (en) * | 2012-12-19 | 2014-06-26 | Merck Sharp & Dohme Corp. | FACTOR IXa INHIBITORS |
| US9708308B2 (en) | 2012-12-19 | 2017-07-18 | Merck Sharp Dohme Corp. | Factor IXa inhibitors |
| EP2934537B1 (en) * | 2012-12-19 | 2018-04-04 | Merck Sharp & Dohme Corp. | Factor ixa inhibitors |
| BR112015023214A8 (pt) | 2013-03-15 | 2019-12-24 | Verseon Corp | composto, composição farmacêutica, e, uso de um composto ou composição farmacêutica |
| PL2968297T3 (pl) * | 2013-03-15 | 2019-04-30 | Verseon Corp | Wielopodstawione związki aromatyczne jako inhibitory protezy serynowej |
| EP3131897B8 (en) | 2014-04-16 | 2022-08-03 | Merck Sharp & Dohme LLC | Factor ixa inhibitors |
| EP3193600A4 (en) * | 2014-09-10 | 2018-05-23 | Epizyme, Inc. | Smyd inhibitors |
| EP3194369A4 (en) | 2014-09-17 | 2018-02-28 | Verseon Corporation | Pyrazolyl-substituted pyridone compounds as serine protease inhibitors |
| US10300154B2 (en) | 2014-09-17 | 2019-05-28 | David R Elmaleh | Anticoagulant derivatives for cardiovascular imaging |
| WO2016087615A1 (en) | 2014-12-04 | 2016-06-09 | Procomcure Biotech Gmbh | Novel imidazole-based heterocyclic compounds |
| WO2016087618A1 (en) | 2014-12-04 | 2016-06-09 | Procomcure Biotech Gmbh | Imidazole-based antimicrobial agents |
| US10351558B2 (en) | 2015-02-16 | 2019-07-16 | Merck Sharp & Dohme Corp. | Factor IXa inhibitors |
| CA2977993A1 (en) | 2015-02-27 | 2016-09-01 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| CN109563081A (zh) * | 2016-04-07 | 2019-04-02 | 葛兰素史克知识产权开发有限公司 | 可用作蛋白调节剂的杂环酰胺类 |
| SI3440076T1 (sl) * | 2016-04-07 | 2022-09-30 | Glaxosmithkline Intellectual Property Development Limited | Heterociklični amidi uporabni kot proteinski modulatorji |
| WO2018093716A1 (en) * | 2016-11-18 | 2018-05-24 | Merck Sharp & Dohme Corp. | FACTOR XIIa INHIBITORS |
| US11040947B2 (en) | 2017-03-22 | 2021-06-22 | The Research Foundation For The State University Of New York | Substituted quinazolines as matrix metalloproteinase-9 hemopexin domain inhibitors |
| ES2942214T3 (es) | 2018-04-17 | 2023-05-30 | Univ Michigan Regents | Inhibidores de la función plaquetaria y procedimientos de utilización de los mismos |
| CN112457308B (zh) * | 2019-09-09 | 2024-01-02 | 上海长森药业有限公司 | 新型三环芳香杂环化合物，及其制备方法、药物组合物和应用 |
| WO2022081573A1 (en) * | 2020-10-12 | 2022-04-21 | University Of Tennessee Research Foundation | Transient receptor potential canonical 3 inhibitors and methods of use thereof |
| JP2023546055A (ja) * | 2020-10-13 | 2023-11-01 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環ｇｌｐ－１アゴニスト |
| CN114149371B (zh) * | 2021-11-26 | 2023-08-22 | 首都医科大学 | 四取代吡唑类化合物及其应用 |
| CN114478511B (zh) * | 2022-02-24 | 2023-06-20 | 中国药科大学 | 苯并恶唑类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| IL106197A (en) | 1992-07-30 | 1999-11-30 | Cor Therapeutics Inc | Agagonists for the rhombin receptors and pharmaceutical preparations containing them |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6063847A (en) | 1997-11-25 | 2000-05-16 | Schering Corporation | Thrombin receptor antagonists |
| KR20010083092A (ko) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드 |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| TWI302913B (en) | 2000-06-15 | 2008-11-11 | Schering Corp | Thrombin receptor antagonists |
| US7235567B2 (en) | 2000-06-15 | 2007-06-26 | Schering Corporation | Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist |
| PL371948A1 (en) | 2001-10-18 | 2005-07-11 | Schering Corporation | Himbacine analogues as thrombin receptor antagonists |
| BR0213562A (pt) * | 2001-10-26 | 2004-08-31 | Aventis Pharma Inc | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna |
| DE60331114D1 (de) | 2002-04-16 | 2010-03-11 | Schering Corp | Trizyklische Thrombinrezeptorantagonisten |
| EP1667983A4 (en) * | 2003-09-23 | 2010-07-21 | Merck Sharp & Dohme | PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS |
| CN1980665A (zh) * | 2004-07-07 | 2007-06-13 | 默克公司 | 吡唑酰胺衍生物，包含这些化合物的组合物和使用方法 |
| JP2008507528A (ja) * | 2004-07-22 | 2008-03-13 | メルク エンド カムパニー インコーポレーテッド | 置換ピラゾール、このような化合物を含有する組成物及び使用方法 |
| JP5063351B2 (ja) * | 2004-09-17 | 2012-10-31 | エグゼリクシス， インコーポレイテッド | ピラゾールキナーゼモジュレーターおよび使用方法 |
| EP1948614A2 (en) * | 2005-11-18 | 2008-07-30 | Takeda San Diego, Inc. | Glucokinase activators |
| US7968683B1 (en) * | 2008-05-07 | 2011-06-28 | Schering Corporation | Factor IXa crystals, related complexes and methods |
| JP2011520897A (ja) * | 2008-05-16 | 2011-07-21 | シェーリング コーポレイション | グルカゴン受容体アンタゴニスト、組成物およびそれらの使用方法 |
-
2009
- 2009-05-18 EP EP09751268A patent/EP2300435A2/en not_active Ceased
- 2009-05-18 US US12/993,607 patent/US8148363B2/en active Active
- 2009-05-18 JP JP2011510610A patent/JP5504259B2/ja not_active Expired - Fee Related
- 2009-05-18 CA CA2724430A patent/CA2724430A1/en not_active Abandoned
- 2009-05-18 WO PCT/US2009/044291 patent/WO2009143039A2/en not_active Ceased
- 2009-05-18 PE PE2009000694A patent/PE20091972A1/es not_active Application Discontinuation
- 2009-05-18 EP EP14173412.9A patent/EP2805939B1/en not_active Not-in-force
- 2009-05-18 CL CL2009001214A patent/CL2009001214A1/es unknown
- 2009-05-18 TW TW098116429A patent/TW201008930A/zh unknown
- 2009-05-18 AR ARP090101778A patent/AR071823A1/es not_active Application Discontinuation
- 2009-05-18 CN CN200980128238XA patent/CN102099340A/zh active Pending
- 2009-05-18 MX MX2010012635A patent/MX2010012635A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2724430A1 (en) | 2009-11-26 |
| EP2805939A1 (en) | 2014-11-26 |
| WO2009143039A2 (en) | 2009-11-26 |
| EP2300435A2 (en) | 2011-03-30 |
| TW201008930A (en) | 2010-03-01 |
| EP2805939B1 (en) | 2018-06-27 |
| WO2009143039A3 (en) | 2010-07-08 |
| CN102099340A (zh) | 2011-06-15 |
| JP5504259B2 (ja) | 2014-05-28 |
| US8148363B2 (en) | 2012-04-03 |
| AR071823A1 (es) | 2010-07-14 |
| MX2010012635A (es) | 2010-12-06 |
| PE20091972A1 (es) | 2010-01-15 |
| JP2011520967A (ja) | 2011-07-21 |
| US20110065682A1 (en) | 2011-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2009001214A1 (es) | Compuestos derivados de heterociclo, moduladores de serina proteasas composicion fa<rmacaeutica que los comprende; y su uso en el tratamiento de trastornos tromboembolicos | |
| CL2007001674A1 (es) | Compuestos derivados de heterociclos, inhibidores de aspartil proteasa; composicion farmaceutica que los comprende;y su uso para tratar enfermedades cardiovasculares,cognitivas y neurodegenerativas. | |
| AR070497A1 (es) | Composicion detergente que comprende lipasa | |
| UY31806A (es) | Compuestos de tiazole y oxazole de sulfonamida de benceno | |
| CL2012000033A1 (es) | Compuestos n-(3-(4as,7as)-2-amino-4a,5,7,7a-tetrahidro-4h-furo[3,4-d][1,3] tiazin-7a-il)-4- fluorofenilo) -5-fluoropiconilamida, inhibidor de bace; composicion farmaceutica que los comprende, uso del compuesto para el tratamiento de la enfermedad de alzheimer. | |
| CR20110100A (es) | Nuevos derivados de sulfamida sustituida | |
| CO6501153A2 (es) | Inhibidores macrociclicos de serina proteasa | |
| HN2007000267A (es) | Compuestos de 4-metil piridopirimidinoma | |
| CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
| AR055428A1 (es) | Escision de precursores de insulinas mediante una variante de tripsina | |
| CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
| CR9869A (es) | Compuestos activos en ppar | |
| SV2009002865A (es) | Uso de oxazolidinonas para el tratamiento y profilaxis de microangiopatias | |
| ES2572160T3 (es) | Una nueva preparación farmacéutica para preeclampsia | |
| CL2007001391A1 (es) | Compuestos derivados de pirrolidinas sustituidas, inhibidores del factor xa y/o inhibidores sobre la serina proteasa; composicion farmaceutica que comprende a dichos compuestos; proedimiento para preparar la composicon farmaceutica; y uso de los compuestos preparar un medicamneto con un efecto antitrombotico | |
| CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
| CR11416A (es) | Algunos derivados de 2-pirazinona y su uso como inhibidores de elastasa de los neutrofilos | |
| CL2015000942A1 (es) | Compuestos de benceno sustituido. | |
| CR20140087A (es) | Anticuerpos a pcsk9 y usos de los mismos | |
| UY30573A1 (es) | N-(1-hetaril-piperidin-4-il)-(het)arilamidas como moduladores del receptor ep2 | |
| BR112012019042A2 (pt) | "inibidores de serina protease tipo tripsina, e sua preparação e uso". | |
| CO6390069A2 (es) | Compuestos de piridina sustituida unida por puente a un heterociclo, como inhibidores de la vía de señalización hedgehog. | |
| SV2011003855A (es) | Heteroarilos sustituidos | |
| CL2012000921A1 (es) | Compuestos derivados de espiropiperidina-metilbenciloxifenil, activadores del receptor rpg-40; composicion farmaceutica que los comprende; y uso del compuesto para tratar diabetes. | |
| GT200600035A (es) | Aminopiridinas como inhibidores de beta-secretasa |